title: Bupropion, smoking cessation, and health-related quality of life following an acute myocardial infarction.
abstract: BACKGROUND
  The use of bupropion, a smoking cessation aid, has been associated with improved health-related quality of life (HRQOL) in the general population of smokers; but, its effect on HRQOL in post-myocardial infarction (MI) patients remains unknown.
  
  
  OBJECTIVE
  To examine the effect of bupropion on HRQOL in post-MI patients who are attempting to quit smoking.
  
  
  METHODS
  To accomplish this objective, we used data from a randomized, double-blind, placebo-controlled trial in 392 hospitalized post-MI patients. Treatment duration was 9 weeks, and follow-up was 12 months. HRQOL was assessed via the EuroQol-5D (EQ-5D) questionnaire, which includes 5 dimensions (mobility, self-care, daily activities, pain/discomfort, and anxiety/depression). Analyses were restricted to patients (n=225) who completed the EQ-5D at baseline, 6 months, and 12 months.
  
  
  RESULTS
  Patients randomized to bupropion (n=109) and those randomized to placebo (n=116) experienced similar improvements in HRQOL during follow-up (difference in change in EQ-5D index from baseline to 6 months = 0.02, 95% confidence interval [CI] = -0.04, 0.08; from baseline to 12 months = 0.02, 95% CI = -0.04, 0.08). No between-group differences were observed in any of the 5 dimensions. Similar improvements in HRQOL were observed between patients who remained abstinent and those who relapsed. Lower baseline HRQOL, defined as having a HRQOL that was less than the median value, was associated with decreased smoking abstinence at 12 months follow-up (odds ratio OR =0.39, 95% CI = 0.22, 0.68).
  
  
  CONCLUSIONS
  Bupropion does not improve HRQOL among patients attempting to quit smoking post-MI.
authors.forename: David Dong Qi
authors.initials: DD
authors.lastname: Zhang
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Eisenberg
authors.forename: Sonia M
authors.initials: SM
authors.lastname: Grandi
authors.forename: Lawrence
authors.initials: L
authors.lastname: Joseph
authors.forename: Jennifer
authors.initials: J
authors.lastname: O'Loughlin
authors.forename: Gilles
authors.initials: G
authors.lastname: Paradis
authors.forename: Pedro
authors.initials: P
authors.lastname: Lozano
authors.forename: Kristian B
authors.initials: KB
authors.lastname: Filion
mesh_terms: D000328:Adult; D016642:Bupropion / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D016017:Odds Ratio; D015995:Prevalence; D011788:Quality of Life; D011792:Quebec / Q000453:epidemiology; D012307:Risk Factors; D040242:Risk Reduction Behavior; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology / Q000523:psychology; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016642:Bupropion